Phase 1: 20, Phase 2: 19, Phase 3: 21, Other: 66
Bayer's pharmaceutical pipeline is concentrated in oncology, cardiovascular disease, and an emerging radioligand therapy (RLT) platform. In oncology, Nubeqa (darolutamide) is an approved androgen receptor inhibitor for non-metastatic and metastatic castration-resistant prostate cancer, with ongoing trials in earlier-line settings. Vitrakvi (larotrectinib) and tepotinib provide kinase inhibitor coverage in TRK-fusion and MET-exon-14 cancers respectively. Bayer's radiopharmaceutical ambitions are reflected in Xofigo (radium-223) for bone-metastatic prostate cancer and a pipeline of targeted RLTs in collaboration with external partners. In cardiovascular, Kerendia (finerenone) for chronic kidney disease with type 2 diabetes, Verquvo (vericiguat) for heart failure, and next-generation Factor XIa inhibitor asundexian represent a deep late-stage CV portfolio. Xarelto (rivaroxaban) continues to generate new indication trials.
- Oncology (prostate, TRK-fusion, radioligand)
- Cardiovascular (Factor Xa/XIa, heart failure)
- Renal / cardiorenal (CKD, finerenone)
- Ophthalmology (VEGF-A/C/D)
- Women's health
- Nubeqa (darolutamide) — AR inhibitor, prostate cancer
- Kerendia (finerenone) — mineralocorticoid receptor antagonist, CKD/T2D
- Xarelto (rivaroxaban) — Factor Xa, thrombosis/AF
- Vitrakvi (larotrectinib) — TRK inhibitor, TRK-fusion cancers
- Verquvo (vericiguat) — sGC stimulator, heart failure
- Asundexian — Factor XIa inhibitor, stroke prevention
Monitor the Bayer pipeline daily
Get alerts when Bayer registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Trials |
|---|---|
| Chronic Kidney Disease | 15 |
| Type 2 Diabetes Mellitus | 9 |
| Hemophilia A | 8 |
| Children | 4 |
| Advanced Solid Tumors | 4 |
| Sepsis | 4 |
| Chronic Heart Failure With Reduced Ejection Fraction | 3 |
| Venous Thromboembolism | 3 |
Bayer's asundexian Factor XIa program is a closely watched anticoagulation alternative to direct oral anticoagulants — major Phase 3 readouts are expected in stroke prevention. Their Nubeqa (darolutamide) earlier-line prostate cancer trials generate competitive intelligence directly relevant to enzalutamide and apalutamide programs at competing firms.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Bayer's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Bayer may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Bayer pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who… NCT06659341 | Recruiting | Completion pushed: 2027-07-30 → 2027-09-06 | 2026-08-27 |
| A Study to Learn More About How Safe the Study Treatment Finerenone is in… NCT05457283 | Recruiting | Completion moved earlier: 2028-12-28 → 2028-11-07 | 2026-08-21 |
| A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome NCT07211685 | Recruiting | Completion moved earlier: 2028-07-27 → 2027-11-29 | 2026-08-21 |
| A Study to Learn More About How Well Sevabertinib Works and How Safe it is… NCT06452277 | Recruiting | Trial sites reduced: 285 → 270 locations | 2026-08-20 |
| A Study to Learn About How a New Nurandociguat Tablet is Absorbed and Processed… NCT07722585 | Recruiting | Recruitment opened | 2026-08-20 |
Each trial page shows every change DataLookout has recorded for that trial.